

Editor's Comment:

I reviewed the original manuscript, the two reviewers comments and the revised manuscript. The work has important scientific value; the experiments were well conducted and were properly analyzed. I fully agreed with the reviewers comments. However there several issues that still need to be addressed in the revision and not mentioned by the reviewers:

1. There were no mention in the text about the potential in-vivo safety (e.g. LD50 values in rodents) or the cytotoxicity of the extracts. Safety is most essential in the discovery and development of new anti-malarial drugs. If such information is known, a statement in the discussion section should clarify this issue.
2. Assuming a good safety consideration concerning these extracts, would the expected human dose of the extracts be similar to artemisinin and its derivatives? Could the authors provide estimates of potential human oral dose from their in-vitro studies described in the experiments? These issues need to be discussed in the revision.
3. The two tables should stand out alone without going back and forth to the text; i.e., we need brief description of the methods and the statistical analysis. The abbreviations should be spelled out and should be explained.
4. I still noted some typographical and grammatical errors in the revised manuscript. Perhaps the editorial office should assist the authors in making these corrections.

Editor's Details:

Dr. Esam Z. Dajani
President, IDDC Corporation, USA
Adjunct Professor of Medicine, Loyola University Chicago, USA